Paradigm Biopharmaceuticals Limited (ASX:PAR)
Australia
· Delayed Price · Currency is AUD 0.255
0.00 (0.00%)
At close: Mar 6, 2026
ASX:PAR Income Statement
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | 2020 - 2016 |
| Operating Revenue | 0.01 | - | - | - | 0.08 | 0.02 | Upgrade
|
| Revenue | 0.01 | - | - | - | 0.08 | 0.02 | Upgrade
|
| Revenue Growth (YoY) | -49.40% | - | - | - | 285.52% | - | Upgrade
|
| Cost of Revenue | 0.01 | 0.02 | 0.01 | 0.02 | 0.14 | 0.1 | Upgrade
|
| Gross Profit | 0 | -0.02 | -0.01 | -0.02 | -0.06 | -0.08 | Upgrade
|
| Selling, General & Admin | 6.05 | 5.58 | 6.77 | 7.39 | 8.85 | 9.59 | Upgrade
|
| Research & Development | 32.78 | 17.74 | 58.33 | 52.68 | 39.01 | 33.52 | Upgrade
|
| Operating Expenses | 38.82 | 23.32 | 65.1 | 60.07 | 47.87 | 43.1 | Upgrade
|
| Operating Income | -38.82 | -23.34 | -65.11 | -60.09 | -47.93 | -43.18 | Upgrade
|
| Interest Expense | -1.32 | -0.01 | -0.01 | -0.02 | -0.03 | -0.04 | Upgrade
|
| Interest & Investment Income | 0.36 | 0.36 | 0.41 | 1.4 | 0.05 | 0.21 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.02 | 0.01 | -0.05 | -0.39 | 0.89 | 0.31 | Upgrade
|
| Other Non Operating Income (Expenses) | 6.21 | 6.75 | 6.04 | 7.09 | 7.76 | 8.4 | Upgrade
|
| EBT Excluding Unusual Items | -33.55 | -16.24 | -58.73 | -52 | -39.25 | -34.3 | Upgrade
|
| Asset Writedown | -2.53 | -2.53 | - | - | - | - | Upgrade
|
| Other Unusual Items | - | - | - | 0.09 | - | - | Upgrade
|
| Pretax Income | -36.09 | -18.77 | -58.73 | -51.91 | -39.25 | -34.3 | Upgrade
|
| Net Income | -36.09 | -18.77 | -58.73 | -51.91 | -39.25 | -34.3 | Upgrade
|
| Net Income to Common | -36.09 | -18.77 | -58.73 | -51.91 | -39.25 | -34.3 | Upgrade
|
| Shares Outstanding (Basic) | 344 | 315 | 293 | 250 | 233 | 230 | Upgrade
|
| Shares Outstanding (Diluted) | 344 | 315 | 293 | 250 | 233 | 230 | Upgrade
|
| Shares Change (YoY) | 7.23% | 7.23% | 17.43% | 7.34% | 1.21% | 14.32% | Upgrade
|
| EPS (Basic) | -0.10 | -0.06 | -0.20 | -0.21 | -0.17 | -0.15 | Upgrade
|
| EPS (Diluted) | -0.10 | -0.06 | -0.20 | -0.21 | -0.17 | -0.15 | Upgrade
|
| Free Cash Flow | -27.42 | -15.99 | -65.94 | -45.19 | -32.21 | -34.96 | Upgrade
|
| Free Cash Flow Per Share | -0.08 | -0.05 | -0.23 | -0.18 | -0.14 | -0.15 | Upgrade
|
| Gross Margin | 24.53% | - | - | - | -81.45% | - | Upgrade
|
| Operating Margin | -459439.36% | - | - | - | -60498.78% | -210124.38% | Upgrade
|
| Profit Margin | -427113.40% | - | - | - | -49542.54% | -166896.27% | Upgrade
|
| Free Cash Flow Margin | -324524.20% | - | - | - | -40650.90% | -170122.95% | Upgrade
|
| EBITDA | -38.67 | -23.19 | -64.97 | -59.93 | -47.74 | -43.13 | Upgrade
|
| D&A For EBITDA | 0.15 | 0.15 | 0.15 | 0.15 | 0.19 | 0.05 | Upgrade
|
| EBIT | -38.82 | -23.34 | -65.11 | -60.09 | -47.93 | -43.18 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.